Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study

Table 3 Polypharmacy among patients receiving at least one medication other than interferon beta1-b (n = 246)

Number of additional medications^a	Number (%) patients^b
Number of additional medications^a	Aged 41–50 years(n = 161)	Aged > 50 years(n = 85)
1	46 (28.6 %)	12 (14.1 %)
2–3	63 (39.1 %)	38 (44.7 %)
≥4	52 (32.3 %)	35 (41.2 %)

^aAdditional medications defined as drugs other than interferon beta-1b.
^b48.2% (161 of 334) aged 41–50 years and 53.8% (85 of 158) aged >50 years were taking additional medications within the safety population (n=492).

ISSN: 1471-2377